 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq...

SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split

TEL AVIV, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...

SciSparc Announces 1-for-26 Reverse Share Split

TEL AVIV, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...

SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities

No Immediate Effect on Nasdaq Listing or Trading of the Company s Ordinary Shares TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a...

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq...

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ:SPRC).About SciSparc Ltd.SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior...

Aegis Capital Corp. acted as Sole Bookrunner on a $1.3 Million Underwritten Public Offering for SciSparc Ltd. (NASDAQ: SPRC)

TEL AVIV, Israel, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ( SciSparc or the Company ) today announced the closing of a firm commitment underwritten public offering with...

SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering

SciSparc slumps 35% on ~$1.3M offering

TEL AVIV, ISRAEL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (SciSparc or the Company) today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.3 million, before deducting underwriting ...

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (SciSparc or the Company) today announced that it intends to offer its securities in a firm commitment underwritten public offering. The Company intends to use the net proceeds from this offering for working capital. ...

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Watchers	3,303
52-Wk Low	$0.1407
52-Wk High	$1.59

Market Cap	$2.68M
Volume (M)	1,148.00
52-Wk High	$1.59
52-Wk Low	$0.1407

SPRC SCISPARC LTD

About

Feed

News

Sentiment

Fundamentals